CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment

F. H. Bouwman, S. N.M. Schoonenboom, W. M. van der Flier, E. J. van Elk, A. Kok, F. Barkhof, M. A. Blankenstein, Ph Scheltens

Research output: Contribution to JournalArticleAcademicpeer-review

147 Citations (Scopus)


Objective: To study CSF biomarkers, beta-amyloid1-42 (Aβ1-42) and tau, and medial temporal lobe atrophy (MTA) on MRI in their ability to predict dementia in patients with mild cognitive impairment (MCI). Methods: Fifty-nine MCI patients (49% male, mean age 69 ± 8), follow-up 19 months, were included. Baseline CSF levels of Aβ1-42, tau and MTA-score were dichotomized. Results: Thirty-three (56%) of the MCI patients progressed to dementia, 30 of which had Alzheimer's disease. Lower CSF Aβ1-42 level, higher CSF-tau and higher MTA-scores at baseline were found in progressed patients. Cox proportional hazards models revealed that abnormal CSF Aβ1-42, CSF tau and MTA were significantly associated with dementia at follow-up (hazard ratio (95% confidence interval): 4.0 (1.3-12.1), 5.9 (1.6-21.7) and 2.1 (1.0-4.6)). A fourfold higher risk was found for patients with both abnormal CSF biomarkers and MTA compared to patients with either test abnormal. Ninety-four percent of patients with both abnormalities converted to dementia. Conclusions: These findings suggest an added value of CSF to MRI in the diagnostic work up of patients presenting at a memory clinic.

Original languageEnglish
Pages (from-to)1070-1074
Number of pages5
JournalNeurobiology of aging
Issue number7
Publication statusPublished - 1 Jul 2007


  • CSF
  • MRI
  • Mild cognitive impairment

Cite this